A Study Evulating DA-302168S Tablets in Overweight/Obese Subjects
Status:
COMPLETED
Trial end date:
2025-01-30
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of continuous oral administration of DA-302168S tablets for 28 days in overweight/obese subjects.